Roche post mixed results for etrolizumab in ulcerative colitis
Phase III study of drug in Crohn’s disease is ongoing
Read Moreby Lucy Parsons | Aug 10, 2020 | News | 0
Phase III study of drug in Crohn’s disease is ongoing
Read Moreby Anna Smith | Apr 24, 2019 | News | 0
A Phase III study found that the primary endpoint for weekly average number of cluster headache attacks during the four-week treatment period is unlikely to be met.
Read Moreby Anna Smith | Jan 3, 2019 | News | 0
Pfizer and Merck KGaA have announced that they will be terminating the Phase III JAVELIN Ovarian 100 study of Bavencio, as the data did not support the study’s initial hypothesis.
Read Moreby Anna Smith | Jan 2, 2019 | News | 0
UK patients with a form of advanced lung cancer will soon be able to access the immunotherapy drug Tecentriq in combination with Avastin, carboplatin and paclitaxel through the Early Access to Medicines Scheme (EAMS).
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
